MAPK14 and ischemia: Various studies have demonstrated that targeted inhibition of p38/JNK protect the myocardium from ischemia and reperfusion injury by reducing oxidative stress, inflammation, cardiomyocyte apoptosis, metabolic abnormalities and by maintaining cytoskeletal architecture (Li et al., 2014; Gao et al., 2015).